- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00508924
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
November 6, 2012 updated by: Mitsubishi Tanabe Pharma Corporation
A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in Comparison With Unfractionated Heparin, Clopidogrel and Aspirin
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of argatroban in reference to unfractionated heparin, in combination with dual antiplatelet therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a phase II multi-centre study in Europe in patients with stable coronary artery disease or troponin negative unstable angina undergoing elective PCI, to obtain the information on the safety and effects on various pharmacodynamic markers, of three doses of argatroban in combination with clopidogrel and aspirin, and to assess the results of argatroban and unfractionated heparin, both used in combination with clopidogrel and aspirin, on clinical outcomes, adequacy of anticoagulation, various pharmacodynamic markers (approximately 35 patients per group).
Study Type
Interventional
Enrollment (Actual)
140
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female (women of child bearing potential must have a negative pregnancy test prior to entry into the study)
- Aged over 18 years
- Diagnosis of stable coronary artery disease (CAD) or unstable angina (troponin negative, i.e. within the normal range for the study site) with low to moderate anatomic risk and a requirement for elective percutaneous coronary angioplasty or stent insertion with an approved device in one or more de novo-treated or re-stenotic lesions in native vessels
- Signed written informed consent
Exclusion Criteria:
- Any condition which, in the investigator's opinion, contraindicates the use of argatroban, heparin or clopidogrel or endangers the patient if he/she participated in this study.
- Known cirrhosis, hepatitis, clinically significant hepatic disorder, or history of hepatic disorder. Hepatic disorder is defined as having levels of liver function tests (bilirubin, Aspartate Aminotransferase (Serum Glutamate Oxaloacetate Transaminase)(AST (SGOT)), Alanine Aminotransferase (Serum Glutamate Pyruvate Transaminase)(ALT (SGPT)) greater than 3.0 times above the upper limit of the normal range of local laboratory.
- Patients not currently taking aspirin
- Renal insufficiency, defined as serum creatinine greater than 2.0 mg/dL (greater than 177mmol/L)
- Platelets less than 125,000/ml
- If already taking any form of heparin prior to study enrolment, Activated Partial Thromboplastin Time(aPTT) equal or greater than 35 sec or ACT greater than 160 sec
- Use of low molecular heparin (LMWH) during 12 h prior to PCI
- If taking oral anticoagulant medication prior to study enrolment, International Normalised Ratio(INR) greater than 1.2
- Q wave MI with cardiogenic shock or thrombolytic therapy within 72 h of study dosing
- Use of Glycoprotein IIb / IIIa(GPIIb/IIIa) inhibitors within prior 3 weeks
- Documented coagulation disorder or bleeding diathesis
- Lumbar puncture within the past 2 weeks
- History of previous cerebral aneurysm, haemorrhagic stroke, or thrombotic stroke within the past 6 months
- Active, uncontrolled peptic ulcer disease or any gastrointestinal bleeding or genitourinary bleeding within 3 months prior to study enrolment
- Major surgery, serious trauma, puncture of non-compressible vessel, or biopsy of parenchymal organ within prior 2 months
- Planned staged procedure, planned rotational atherectomy, directional coronary atherectomy, brachytherapy, or thrombectomy catheters
- Planned surgical intervention other than study procedure within next 7 days
- Presence of greater than 50% stenosis of unprotected left main coronary artery
- Severe peripheral vascular disease, precluding femoral access
- History of vasculitis
- Uncontrolled hypertension defined as greater than 180/120 mmHg
- Pregnancy (exclusion by routine urine test)
- Lactating woman
- Woman of children bearing age who are or were not using accepted contraceptive methods
- Participation in other clinical trials of investigational products within 3 months prior to study enrolment
- Terminally ill patients with a life expectancy of < 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARG250
|
|
EXPERIMENTAL: ARG300
|
|
EXPERIMENTAL: ARG350
|
|
PLACEBO_COMPARATOR: Heparin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.
Time Frame: 5 - 10 min after initial bolus
|
5 - 10 min after initial bolus
|
|
Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.
Time Frame: 30 Days
|
Composite end point (a): all cause death, myocardial infarction and urgent revascularization at Day30 Composite end point (b): all cause death, myocardial infarction and urgent revascularization at Day30 as well as major bleeding events during hospital stay |
30 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Study Completion (ACTUAL)
October 1, 2006
Study Registration Dates
First Submitted
July 26, 2007
First Submitted That Met QC Criteria
July 26, 2007
First Posted (ESTIMATE)
July 30, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
December 5, 2012
Last Update Submitted That Met QC Criteria
November 6, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Pain
- Neurologic Manifestations
- Coronary Disease
- Chest Pain
- Angina Pectoris
- Coronary Artery Disease
- Angina, Unstable
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Protease Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Heparin
- Argatroban
Other Study ID Numbers
- ARG-E04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Heparin
-
San Filippo Neri General HospitalUniversity of Roma La SapienzaUnknownAngina, Unstable | Stable Angina | Non-ST Elevation (NSTEMI) Myocardial InfarctionItaly
-
Robert F. JamesIndiana University School of MedicineSuspendedNeurobehavioral Manifestations | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, Intracranial | Intracranial Aneurysm | Heparin-induced Thrombocytopenia Type IIUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownRenal Failure | HemodialysisItaly
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Christine RibicMcMaster University; LEO PharmaCompleted
-
The University of Texas Health Science Center at...WithdrawnThrombosis | Anticoagulants | Infant, PrematureUnited States
-
Azidus BrasilSuspendedChronic Renal FailureBrazil
-
Regado Biosciences, Inc.CompletedAcute Coronary Syndrome (ACS)United States, Canada, Germany, France
-
University of OklahomaRecruitingRecurrent Urinary Tract InfectionsUnited States
-
McMaster UniversityCompleted